Evidence map›Paper›PMID 41934107›Full record

ArticleRheumatology (Oxford, England)2026

Diarrhoea events in offspring exposed to tumour necrosis factor inhibitors and rotavirus vaccine: a population-based cohort study.

Leah K Flatman, Marie-Eve Beauchamp, Yvan St-Pierre, Isabelle Malhamé, Anick Bérard, Sasha Bernatsky, Évelyne Vinet

Abstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Leah K FlatmanDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-3719-1248
Marie-Eve BeauchampCentre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.ORCID 0000-0001-9488-0157
Yvan St-PierreCentre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Isabelle MalhaméCentre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.ORCID 0000-0002-9140-8735
Anick BérardFaculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.ORCID 0000-0001-7535-5517
Sasha BernatskyDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-9515-2802
Évelyne VinetDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.ORCID 0000-0001-7727-5879

Funding

CIHR FRN-181503CIHR PJT-166075CIHR PJT-180634Fonds de recherche du Québec-Santé senior salarythe Arthritis Society STAR-19-0597
6 · The paper itself

Abstract

objectivesPreviously, TNF inhibitor (TNFi)-exposed infants were recommended to withhold rotavirus vaccination until 6 months due to infection risk. Guidelines have recently supported earlier vaccination, although safety data remain limited. We aimed to compare diarrhoea risk (during early [1.5-6 months] and later [6-24 months] infancy) in TNFi-exposed infants who received rotavirus vaccination before 6 months vs those unvaccinated by 6 months.

methodsWe identified 3167 TNFi-exposed offspring in MarketScan commercial claims born to mothers with chronic inflammatory diseases between 2011 and 2021. Early vaccination was defined as ≥1 rotavirus dose between 1.5 and 6 months and modelled as time-varying. Diarrhoea events were identified using ICD-9/10 codes from hospitalizations, outpatient visits or emergency department visits. Cox proportional hazards models estimated hazard ratios (HR) and 95% CI for diarrhoea events in vaccinated vs unvaccinated infants.

resultsAmong TNFi-exposed offspring, no statistically significant association was found between early vaccination and diarrhoea risk during early (101 events; HR 1.04; 95% CI 0.65, 1.68) or later infancy (283 events; HR 1.16; 95% CI 0.87, 1.55). Patterns remained consistent among infants exposed to TNFi in the third trimester (1.5-6 months: HR 1.07; 95% CI 0.62, 1.85; 6-24 months: HR 1.10; 95% CI 0.79, 1.52) and those exposed to high-placental transfer TNFi in the third trimester (1.5-6 months: HR 0.93; 95% CI 0.51, 1.70; 6-24 months: HR 1.09; 95% CI 0.77, 1.56).

conclusionEarly rotavirus vaccination in TNFi-exposed infants did not increase diarrhoea risk, even for those exposed late in pregnancy. Findings support early vaccination and reinforce updated recommendations.

Indexed as

DiarrheaPrenatal Exposure Delayed EffectsRotavirus InfectionsRotavirus VaccinesTumor Necrosis Factor-alphaAdultCohort StudiesFemaleHumansInfantInfant, NewbornMalePregnancyVaccinationRotavirus VaccinesTumor Necrosis Factor-alphaadministrative databasebiologic therapychildhood immunizationinfant healthobservational cohort studypharmacoepidemiologypregnancy exposurerotavirus immunizationTNFi

Identifiers

PMID41934107
PMCPMC13091608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.